DSG3 and acquired polycythemia vera: Ellebrecht et al. applied this concept to PV, suggesting that expression of Dsg3 as the extracellular domain of a CAR should specifically target cytotoxic responses to those B-lymphocytes bearing anti-Dsg3 B-cell receptors; this should result in a targeted therapy avoiding general immunosuppression (96).